Blackhawk Capital Partners’s Moderna MRNA Stock Holding History
Bought
Maintained
Sold
Other funds holding MRNA
FP
TP
Blackhawk Capital Partners's MRNA Position: Q2 2023 in Review
Blackhawk Capital Partners sold out of Moderna (MRNA) in Q2 2023, closing a stake of 5,460 shares — an estimated $839K sold.
Blackhawk Capital Partners first reported a position in MRNA in Q4 2022 and held it in 2 quarters. The position peaked at $839K in Q1 2023. 965 funds tracked by Wall St. Rank hold MRNA as of Q2 2023.
- Blackhawk Capital Partners reported no remaining Moderna position as of Q2 2023 after selling out during the quarter.
- Blackhawk Capital Partners sold 5,460 Moderna shares in Q2 2023, an estimated $839K.
- Blackhawk Capital Partners first reported a position in Moderna in Q4 2022 and held it in 2 quarters.
- Blackhawk Capital Partners's Moderna position peaked at $839K in Q1 2023.
- 965 funds tracked by Wall St. Rank held Moderna as of Q2 2023.
Based on Blackhawk Capital Partners's 13F filing for Q2 2023, filed 18 Jul 2023.